Back to Search
Start Over
Gemtuzumab Ozogamicin (Mylotarg) as a single agent for moleculary relapsed acute promyelocytic leukemia
- Publication Year :
- 2004
- Publisher :
- American Society of Hematology:1900 M Street Northwest, Suite 200:Washington, DC 20036:(800)633-4931, (202)776-0544, EMAIL: publishing@hematology.org, ash@hematology.org, INTERNET: http://www.hematology.org, Fax: (202)776-0551, 2004.
-
Abstract
- The anti-CD33 antibody calicheamicinconjugate gemtuzumab ozogamicin (GO) was used to treat 16 patients with acute promyelocytic leukemia (APL) who had relapsed at the molecular level. Of these patients, 8 were experiencing a first, 5 a second, 2 a third, and 1 a fourth relapse. GO was administered at 6 mg/m2 for 2 doses, and patients achieving a new molecular remission (MR) (ie, negativity of the reverse transcriptase-polymerase chain reaction [RT-PCR] test for PML/RARalpha) received a third dose. MR was obtained in 9 (91%) of 11 patients tested after 2 doses and in 13 (100%) of 13 patients tested after the third dose. Of the 3 remaining patients, 1 achieved MR after one GO administration and received no further therapy owing to hepatic toxicity, and 2 showed disease progression during treatment. Quantitative RT-PCR studies showed that responding patients experienced a dramatic decline (at least 2 logs) of the PML/RARalpha transcript after the first GO dose. Of 14 responders, 7 remained in sustained MR for a median of 15 months (range, 7-31 months) while 7 experienced relapse at 3 to 15 months. GO was administered again in 2 patients with relapse, and both obtained a new MR. These data indicate that GO is highly effective as a single treatment for patients with molecularly relapsed APL including those with very advanced disease.
- Subjects :
- Oncology
Male
Time Factors
medicine.medical_treatment
Biochemistry
Antineoplastic Agent
chemistry.chemical_compound
Leukemia, Promyelocytic, Acute
Recurrence
MED/15 - MALATTIE DEL SANGUE
Reverse Transcriptase Polymerase Chain Reaction
Progressive multifocal leukoencephalopathy
Immunotoxins
Remission Induction
Antibodies, Monoclonal
Hematology
Middle Aged
Gemtuzumab
Leukemia
Treatment Outcome
Monoclonal
Disease Progression
Female
medicine.drug
Human
Acute promyelocytic leukemia
Adult
medicine.medical_specialty
Adolescent
Time Factor
Gemtuzumab ozogamicin
Immunology
Antineoplastic Agents
Antibodies, Monoclonal, Humanized
Disease-Free Survival
Internal medicine
Calicheamicin
medicine
Humans
Aged
Chemotherapy
Aminoglycoside
business.industry
Cell Biology
medicine.disease
Surgery
Clinical trial
Aminoglycosides
chemistry
business
Settore MED/15 - Malattie del Sangue
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....d18fe42c61863493c76f92cb3288267f